Project

Developing Antioxidative Nanoparticle Medicine (RNP) for Cerebral Infarction

Summary

In Japan, an estimated 186,000 people suffer cerebral infarction per year. Acute phase treatment of cerebral infarction has progressed with the introduction of thrombolytic medicines (t-PA) and thrombectomies (recanalization using catheters). However, despite such acute phase treatment and rehabilitation, many patients suffer from speech disorders, paralysis and other secondary effects that prevent them from returning home or reintegrating into society. Stroke, including cerebral infarction, is the third highest cause of death.

 

Several drugs have been developed so far and basic experiments and clinical trials have been conducted to find a neuroprotective medicine effective against cerebral infarction. However, no such medicine is available for use worldwide. Therefore, in this study, we are developing, testing efficacy and researching practical application of neuroprotective antioxidative nanoparticle medicine (RNP) with active-oxygen scavenging activity that can be used in the acute phase of cerebral infarction. We have already tested the efficacy and safety of RNPs using animal models as well as its mechanism of action (Marushima, Matsumura, et al. Neurosurgery 2011, Hosoo, Marushima, Matumura, Stroke 2017). Moving forward toward practical implementation, we plan to verify usage methods with applied diseases, undertake RNP manufacture and quality evaluation in collaboration with companies and conduct preclinical tests (safety tests).

 

 

 

 

 

 

Developing Neuroprotective Therapy Methods Through Antioxidative Nanoparticle Medicine (RNP) for Cerebral Infarction:
https://neurosurgery-tsukuba.com/content/files/kiso/8.pdf

Company

Bio-functional Control and Regenerative Research Group

Main member